Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines?

Harold J. Burstein, Martine J. Piccart-Gebhart, Edith A. Perez, Gabriel N. Hortobagyi, Norman Wolmark, Kathy S. Albain, Larry Norton, Eric P. Winer, Clifford A. Hudis

Research output: Contribution to journalComment/debate

33 Scopus citations
Original languageEnglish (US)
Pages (from-to)2179-2182
Number of pages4
JournalJournal of Clinical Oncology
Volume30
Issue number18
DOIs
StatePublished - Jun 20 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Burstein, H. J., Piccart-Gebhart, M. J., Perez, E. A., Hortobagyi, G. N., Wolmark, N., Albain, K. S., Norton, L., Winer, E. P., & Hudis, C. A. (2012). Choosing the best trastuzumab- based adjuvant chemotherapy regimen: Should we abandon anthracyclines? Journal of Clinical Oncology, 30(18), 2179-2182. https://doi.org/10.1200/JCO.2012.42.0695